Sugentech Inc (253840) - Total Liabilities
Based on the latest financial reports, Sugentech Inc (253840) has total liabilities worth ₩21.45 Billion KRW (≈ $14.53 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sugentech Inc - Total Liabilities Trend (2017–2025)
This chart illustrates how Sugentech Inc's total liabilities have evolved over time, based on quarterly financial data. See Sugentech Inc (253840) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Sugentech Inc Competitors by Total Liabilities
The table below lists competitors of Sugentech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Actuate Therapeutics, Inc. Common stock
NASDAQ:ACTU
|
USA | $6.78 Million |
|
Inspirisys Solutions Limited
NSE:INSPIRISYS
|
India | Rs2.32 Billion |
|
Dc Infotech And Communication Limited
NSE:DCI
|
India | Rs1.91 Billion |
|
Etherstack Plc
AU:ESK
|
Australia | AU$11.07 Million |
|
Ascent Solar Technologies, Inc. Common Stock
NASDAQ:ASTI
|
USA | $3.00 Million |
|
Ralco Agencies Ltd
TA:RLCO
|
Israel | ILA71.02 Million |
|
Turism Felix B
RO:TUFE
|
Romania | RON65.86 Million |
|
Yura Tech. Co. Ltd
KQ:048430
|
Korea | ₩32.47 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Sugentech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Sugentech Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.82 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sugentech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sugentech Inc (2017–2025)
The table below shows the annual total liabilities of Sugentech Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩21.67 Billion ≈ $14.68 Million |
+106.09% |
| 2024-12-31 | ₩10.51 Billion ≈ $7.13 Million |
-49.28% |
| 2023-12-31 | ₩20.73 Billion ≈ $14.05 Million |
-36.64% |
| 2022-12-31 | ₩32.72 Billion ≈ $22.17 Million |
-40.35% |
| 2021-12-31 | ₩54.85 Billion ≈ $37.17 Million |
+486.64% |
| 2020-12-31 | ₩9.35 Billion ≈ $6.34 Million |
-55.71% |
| 2019-12-31 | ₩21.11 Billion ≈ $14.31 Million |
+136.82% |
| 2018-12-31 | ₩8.92 Billion ≈ $6.04 Million |
-82.55% |
| 2017-12-31 | ₩51.09 Billion ≈ $34.62 Million |
-- |
About Sugentech Inc
Sugentech Inc. develops and sells in-vitro diagnostic systems and products based on biotechnology, information technology, and nanotechnology in South Korea and internationally. The company offers lab tests, including systems and test items; and COVID-19 tests. It also provides point of care testing analyzers and test items for testing of influenza A/B, antibody test, COVID-19 and flu, SARS-CoV-2… Read more